We employ a differentiated &
de-risked investment strategy creating a portfolio targeting all causes of aging.
A science based investing approach focusing on:
3-5 Years
to Exit
Growth Stage
(Series B+)
Platform Tech
(Multiple Assets)
Our investment focus areas
Gene Therapies
& Editing
Cell Therapies
& Regenerative Medicine
AI Drug Discovery
& Early Diagnostics
AI-Powered Medtech
& Biosensing